Range of benefits - Interpharma

Healthcare system

Range of benefits

The options for funding an increasingly complex healthcare system are limited – and they require a new way of looking at costs.

Overview HTA cost-effectiveness assessments DRG hospital funding Range of benefits

Compared with other countries, Switzerland has a uniform and generous range of benefits, covering everything reimbursed by the statutory health insurance (SHI) system. Its broad scope limits the transfer of costs and ensures that the entire population has access to high-quality medical care.

Medical services and products must meet the WZW criteria (the acronym derives from the German words) of effectiveness, appropriateness and cost-effectiveness before they can be included in the range of benefits provided by the statutory health insurance system and thus reimbursed by the health insurers. The Health Insurance Act (HIA) requires the included benefits to be reviewed periodically. This task falls to the Federal Office of Public Health (FOPH). The FOPH examines new benefits and products at the manufacturer’s request; the manufacturer must provide evidence that they comply with the WZW criteria. If they are assessed positively by the FOPH, medicinal products are included in the List of pharmaceutical specialities (LS); this list contains all the medicinal products and therapies reimbursed under basic health insurance.

Curative benefits are covered by basic health insurance provided they have not been specifically excluded. The manufacturer must also provide evidence of the effectiveness, appropriateness and cost-effectiveness of medicinal products, laboratory analyses and other agents used for examination and treatment purposes if the intention is for them to be covered and reimbursed under basic health insurance.

Complementary medicine

In 2017, regulations came into force that put complementary medicine benefits on an equal footing with the other medical benefits provided by the SHI system. Under certain conditions (a tradition of use and research, scientific evidence and medical experience, postgraduate medical training), medical care provided by doctors practising anthroposophic medicine, traditional Chinese medicine, homeopathy and plant-based therapy are accepted in good faith and reimbursed by the SHI system. The principle of good faith presupposes that doctors only provide services that fulfil the requirements for effectiveness, appropriateness and cost-effectiveness. As with other branches of medicine, only certain, controversial services undergo scrutiny.

Further information

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2020

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more